An ISS-based study identified a key point of reduced gravity where mice begin to lose muscle. The threshold is well above the ...

The company's clinical development plan comprises three global Phase III studies, including two focused on infants and a third for older patients.

Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies for spinal muscular atrophy, Duchenne muscular dystrophy and Becker muscular ...

This time, her baby did test positive for SMA type 1, a severe neurodegenerative genetic condition that typically results in ...

Biogen’s salanersen is now heading into three Phase III trials in SMA.

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA, ...

Mutations that cause spinal muscular atrophy (SMA) may lead to abnormalities in the development of cells in the spinal cord, a study found.

Biogen has launched a trio of Phase 3 trials to test salanersen, a new SMA treatment that aims to be a more convenient ...

STELLAR-2, a randomized, double-blind, sham-controlled study, will evaluate the effects of salanersen when initiated ~6 months after onasemnogene abeparvovec-xioi in infants with SMA who received ...

Videos of astronauts on the Moon show them often bouncing across the lunar surface, helped by the fact that the gravity of our satellite is just one-sixth of Earth’s surface gra ...